Episode 724
TWiV 724: COVID-19 clinical update #51 with Dr. Daniel Griffin
February 27, 202136m 57s
Audio is streamed directly from the publisher (traffic.libsyn.com) as published in their RSS feed. Play Podcasts does not host this file. Rights-holders can request removal through the copyright & takedown page.
Show Notes
In COVID-19 clinical update #51, Daniel Griffin reviews use of two masks, effectiveness of testing in nursing homes, updates on vaccines, use of nonsteroidal anti-inflammatory drugs, little effect of vitamin D and remdesivir in clinical studies, and a long COVID research initiative from NIH.
Hosts: Daniel Griffin and Vincent Racaniello
Subscribe (free): iTunes, Google Podcasts, RSS, email
Become a patron of TWiV!
Links for this episode- Updated NYC mask guidance (NYC Health)
- Two masks recommended (CDC)
- Effectiveness of testing in nursing homes (Clin Inf Dis)
- Vaccine reactogenicity and antibody response after COVID-19 (medRxiv)
- Bamlanivimab alone or with Etesevimab (JAMA)
- Non-steroidal anti-inflammatory drugs and death (BMJ)
- Budesonide and COVID-19 (medRxiv)
- No effect of vitamin D high dose (JAMA)
- Remdesivir little effect on hospitalized patients (NEJM)
- Sequelae 6 months after infection (JAMA)
- Long COVID initiative (NIH)
- Letters read on TWiV 724
- Timestamps by Jolene. Thanks!
Intro music is by Ronald Jenkees Send your questions for Dr. Griffin to [email protected]